News headlines about Hill-Rom (NYSE:HRC) have been trending positive this week, according to Accern. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Hill-Rom earned a daily sentiment score of 0.25 on Accern’s scale. Accern also gave headlines about the medical technology company an impact score of 46.9417655085005 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the headlines that may have impacted Accern’s analysis:
A number of analysts have commented on the company. KeyCorp reiterated a “buy” rating and issued a $94.00 price objective on shares of Hill-Rom in a research report on Thursday, December 21st. Raymond James Financial upgraded Hill-Rom from a “market perform” rating to an “outperform” rating and set a $94.00 target price for the company in a research report on Wednesday, January 3rd. Morgan Stanley downgraded Hill-Rom from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 2nd. They noted that the move was a valuation call. Zacks Investment Research downgraded Hill-Rom from a “buy” rating to a “hold” rating in a research report on Tuesday, March 6th. Finally, Needham & Company LLC restated a “buy” rating and set a $105.00 target price (up previously from $90.00) on shares of Hill-Rom in a research report on Tuesday, January 16th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $93.89.
Shares of NYSE HRC traded down $1.73 during midday trading on Friday, hitting $84.45. The stock had a trading volume of 224,785 shares, compared to its average volume of 406,898. The stock has a market capitalization of $5,588.39, a P/E ratio of 20.96, a price-to-earnings-growth ratio of 1.36 and a beta of 0.97. Hill-Rom has a fifty-two week low of $69.47 and a fifty-two week high of $91.11. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.29 and a current ratio of 1.75.
Hill-Rom (NYSE:HRC) last released its earnings results on Friday, January 26th. The medical technology company reported $0.92 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.79 by $0.13. The company had revenue of $669.70 million during the quarter, compared to analysts’ expectations of $670.00 million. Hill-Rom had a return on equity of 20.24% and a net margin of 7.14%. The business’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same period last year, the firm earned $0.75 EPS. equities research analysts forecast that Hill-Rom will post 4.62 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, March 30th. Stockholders of record on Friday, March 23rd were given a $0.20 dividend. This is a positive change from Hill-Rom’s previous quarterly dividend of $0.18. This represents a $0.80 annualized dividend and a dividend yield of 0.95%. The ex-dividend date was Thursday, March 22nd. Hill-Rom’s dividend payout ratio (DPR) is currently 20.73%.
COPYRIGHT VIOLATION NOTICE: This story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/04/08/hill-rom-hrc-getting-favorable-media-coverage-report-finds.html.
Hill-Rom Holdings, Inc is a global medical technology company. The Company partners with health care providers across care settings, by focusing on patient care solutions that improve clinical and economic outcomes in five core areas: advancing mobility, wound care and prevention, patient monitoring and diagnostics, surgical safety and efficiency and respiratory health.
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.